bpc 157 human clinical trials safety regulatory status fda warning As unregulated peptides grow in popularity, doctors warn of unknown risks BPC-157: What the Science Actually

the compositions may be administered in conjunction with other treatatent modalities such as other agents which are used to treat, for example, dementia or the conditions which cause dementia in the patient, examples of which include but are not limited to the administration of anti-depressants and psychoactive drugs, administration of dopamine and similar agents

Overall signal: Reviews summarize broad preclinical benefits but emphasize minimal human data and the need for trials before clinical adoption

Int J Obes (Lond)

FDA announced it was downclassifying a slew of medical devices to class II with special controls